Trevi Therapeutics has closed a public offering of 13.34 million shares at $13.00 per share for gross proceeds of approximately $173 million, including the full exercise of the 1.74 million-share overallotment option. All shares were sold by the company.
The raise gives Trevi fresh capital to advance Haduvio (oral nalbuphine ER) across chronic cough indications in idiopathic pulmonary fibrosis (IPF), non‑IPF interstitial lung disease, and refractory chronic cough. The company has reported statistically significant cough reductions in prior trials in IPF chronic cough and in refractory chronic cough, positioning the program to move into costlier late-stage development and preparatory commercialization work. A four-bank bookrunner lineup and full greenshoe exercise suggest solid institutional demand for the story in a market that has been selective on small-cap respiratory assets.
Strategically, this looks like a scale-up moment. The financing size is consistent with running one or more global Phase 3 programs, expanding long-term safety exposure, and locking in CMC and supply for an extended-release opioid modulator. It also creates room to invest in endpoint infrastructure that cough trials now require, namely objective 24‑hour cough monitoring, centralized data handling, and tighter placebo control. With P2X3 antagonists navigating tolerability and mixed regulatory outcomes, Trevi is leaning into a mechanistic alternative that could sidestep class‑specific issues while taking on its own risk profile. Nalbuphine’s status as not scheduled by the U.S. DEA reduces site and distribution friction relative to controlled substances, but the opioid pharmacology will still drive close scrutiny of CNS adverse events and abuse-deterrence narratives as exposure scales.
For sites, expect an uptick in activation at ILD referral centers and pulmonary clinics with experience in objective cough endpoints. Studies in IPF cough carry operational constraints: small, fragile populations, background antifibrotic use, and attrition tied to disease progression. Sites will need reliable access to cough-monitoring hardware, calibration procedures, and workflow integration to minimize data loss. CROs with respiratory depth and digital endpoint operations are likely to benefit, particularly those that can standardize ambulatory cough counting across geographies and ensure consistency in diary and PRO capture. Vendors supporting device logistics, central analytics, and patient adherence will be central to execution.
For regulators, the key questions remain endpoint selection, clinical meaningfulness thresholds, and durability. Agencies have pushed for objective cough frequency as a primary measure, with supportive PROs to anchor patient benefit. In IPF and other ILDs, symptomatic relief without disease modification can be acceptable if effect sizes are robust and safety is clean over longer windows. The opioid receptor mechanism will draw attention to neuropsychiatric events, somnolence, and discontinuations, and to any signals that could complicate chronic use. The non-scheduled status helps, but scheduling can be revisited as programs scale, so risk management plans will matter.
The near-term watch list is straightforward: Phase 3 design disclosures, including primary endpoints, duration, and geographic mix; clarity on whether Trevi prioritizes IPF cough, non‑IPF ILD cough, or RCC first; timing for regulatory interactions that might support expedited pathways; and expansion of manufacturing for extended-release nalbuphine. Competitive dynamics in cough could tighten if next‑generation P2X3s deliver cleaner tolerability, heightening recruitment pressure and raising the bar on effect size. The new capital likely funds through at least one pivotal readout; whether it also covers pre-commercial build will depend on trial scope and burn.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
